Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

Search through Resources

Home

Clinical Updates Calendar

View All Resources

Search through Resources

Early FLAURA2 Data Show Osimertinib-Chemotherapy Benefit Holds Regardless of Baseline TP53 Status in EGFR+ NSCLC

FLAURA2 Data Show Declining AE Frequency Across Osimertinib Treatment Periods in EGFR+ NSCLC

Firmonertinib 160 mg Demonstrates Efficacy in EGFR-Mutated NSCLC With Leptomeningeal Mets

FLAURA2 Data Show Osimertinib-Chemotherapy Benefit Holds Regardless of Baseline TP53 Status in EGFR+ NSCLC

Silevertinib Yields Significant Response Rates in Frontline EGFR Non-Classically–Mutated NSCLC

Osimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLC

EGFR Channel News Network: On Location at ILCC 2026 with Dr. Olivia Fankuchen

FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Exploratory 8-Year Overall Survival Landmark Update

TP53 Mutations in EGFR-Mutant and Risk Stratification

EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options

Future Directions: Toward Personalized EGFR Therapy in NSCLC

EGFR-Mutated NSCLC: Impact of Subcutaneous Administration on Treatment Experience

AMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC

Liquid Biopsy Shows High Concordance With Tissue Biopsy for EGFR Detection in Stage III NSCLC

Adverse Events Prompting Dose Modification in EGFR-Mutated NSCLC

FLAME Data and the Role of ctDNA

Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLC

DZD6008 Demonstrates Salvage Potential in EGFR C797X–Mutant NSCLC

Osimertinib (osi) With or Without Chemotherapy (CTx) as First-line Treatment in EGFR-mutant (EGFRm) Advanced NSCLC With Concurrent TP53 Mutations (TOP Study)

Emerging TKIs Drive Renewed Progress in EGFR Exon 20 Insertion–Positive NSCLC

Adding LCT to Osimertinib Improves PFS Outcomes, Local Control Rates in EGFR-Mutated NSCLC

BH-30643 Shows Activity in EGFR C797S+ NSCLC After Resistance to Prior TKI

Osimertinib Plus Gefitinib Suppresses Acquired EGFR Resistance Mutations in First-Line NSCLC

Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC

TP53 Co-Mutations and Prognosis in EGFR-Mutated NSCLC

Key Takeaways and Future Directions in EGFR-Mutated Advanced NSCLC

Optimizing Treatment Selection in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence

Factors Informing First-Line Treatment Selection in EGFR-Mutated NSCLC

MET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity Management

Chemotherapy (chemo) Rechallenge in Patients (pts) With Egfr-mutated (EGFRm) Advanced NSCLC Who Discontinued 1L Osimertinib (osi) + Platinum–pemetrexed (plat-pem) Due to Progression (PD): FLAURA2 Exploratory Analysis

Interpreting FLAURA2 for Sequencing Strategies in EGFR-Mutant NSCLC

MET TKIs and ADCs May Broaden Post-Osimertinib Treatment Options in EGFR-Mutant NSCLC

Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLC

Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC

Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC

Identifying High-risk Patient Populations Benefitting From Combination Therapy in the Frontline

Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLC

Biomarker Testing and Access Barriers in EGFR-Mutated NSCLC

Multidisciplinary Toxicity Management in EGFR-Mutated NSCLC

Second-Line Sequencing After Frontline Progression in EGFR-Mutated NSCLC

The Importance of Combination Therapy: Understanding Chemotherapy’s Role in Modern EGFR+ Treatment

Sunvozertinib Improves PFS Over Chemotherapy in First-Line EGFR Exon 20–Mutant NSCLC

Shared Decision-Making and Risk Stratification in EGFR-Mutant NSCLC

Amivantamab Plus Lazertinib Produces Clinically Meaningful OS in Atypical EGFR-Mutated Advanced NSCLC

Datopotamab Deruxtecan and ADC Toxicity Management in EGFR-Mutant NSCLC

Sequencing Strategy in EGFR-Mutant NSCLC: How Frontline Choices Shape Later Options

Practical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of Life

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance

EGFR-Mutated NSCLC: Acquired Resistance

Future Directions and Unmet Needs in EGFR-Mutant NSCLC

EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment

Preclinical Data for EPI-326 Support Clinical Research in EGFR-Responsive Solid Tumors

Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC

Ongoing Research to Watch in EGFR-Mutated NSCLC

Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression

Neoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC

Dr. Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC

Pemetrexed Maintenance Duration and Toxicity Management

EGFR-Mutated NSCLC: Using Post-Progression Data to Guide 1L Strategies

VRN110755 Elicits Responses With Manageable Safety in EGFR C797S+ NSCLC

AMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC Infographic

Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC Infographic

Sacituzumab Tirumotecan Elicits Responses in Previously Treated NSCLC With AGAs Other Than Classical EGFR Mutations

Intercalated Gefitinib Plus Chemotherapy Improves DFS in Resected EGFR-Mutant NSCLC

TP53 Co-Mutation and the TOP Study

Poor Prognostic Factors and Frontline Treatment Selection

Real-World Experience and Integrating FLAURA2, TOP, and FLAME Into Practice

Lung Cancer Experts Debate Disease Nuances to Deliver Patient-Centered Care

EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options Infographic

Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC Infographic

Keeping Future Options Open: Flexibility Across the EGFR Treatment Journey

Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC

Understanding the Differences Between Chemotherapeutic Agents: The Misconception Driving Today’s Conversations

EGFR Channel News Network: On Location at ILCC 2026 with Dr. Deborah Doroshow and Dr. Amin Nassar

Targeted Therapy Pushes Into Locally Advanced NSCLC as Questions of Duration and Cure Persist

How Subcutaneous Amivantamab Fits into EGFR-Mutated NSCLC Management

The Role of Tumor Burden on Treatment Selection in EGFR-Mutated NSCLC

Time Toxicity and Treatment Selection in EGFR-Mutated NSCLC

FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC